Represents the amount to be paid by the entity on achievement of various milestones.

No definition available.

Name:	opht_AmountToBePaidOnAchievementOfMilestone
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Clinical And Marketing Approval Milestones

+ References

No definition available.

+ Details

Name:	opht_AssetAcquisitionClinicalAndMarketingApprovalMilestones
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration Arrangements, Contingently Issuable Shares As A Percentage Of Shares Outstanding

+ References

No definition available.

+ Details

Name:	opht_AssetAcquisitionContingentConsiderationArrangementsContingentlyIssuableSharesAsAPercentageOfSharesOutstanding
Namespace Prefix:	opht_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Shares Issuable, High

+ References

No definition available.

+ Details

Name:	opht_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesSharesIssuableHigh
Namespace Prefix:	opht_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High

+ References

No definition available.

+ Details

Name:	opht_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	opht_CommitmentsAndContingenciesLineItems
Namespace Prefix:	opht_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Licensed Products

+ References

No definition available.

+ Details

Name:	opht_NumberofLicensedProducts
Namespace Prefix:	opht_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments for License Fees

+ References

No definition available.

+ Details

Name:	opht_PaymentsforLicenseFees
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount awarded to other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=opht_ArchemixCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=opht_C5LicensedProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedClinicalAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_FirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_SecondandThirdIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_SustainedDeliveryApplicationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=opht_RHOadRPLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=opht_UniversityofFloridaResearchFoundationUFRFMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_SpecifiedClinicalMarketingApprovalandReimbursementApprovalMilestonesRelatedtoaLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_SpecifiedCommercialSalesMilestonesRelatedtoaLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_AssetAcquisitionAxis=opht_Inception4Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=opht_GAProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=opht_WetAMDProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=opht_BEST1LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=opht_UniversityOfFloridaResearchFoundationUFRFAndUniversityOfPennsylvaniaPennMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=opht_PrimaryLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=opht_OtherLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Narrative (Details) shares in Millions, $ in Millions			1 Months Ended
	Mar. 12, 2019 USD ($)	Oct. 30, 2018 USD ($) shares	May 31, 2019 USD ($) licensed_product	Jun. 30, 2018 USD ($)	Sep. 30, 2011 USD ($)
Commitments and contingencies
Number of licensed products \| licensed_product			1
Fees and costs paid to plaintiff's counsel	$ 0.3
License Agreements \| Archemix \| C5 Licensed Product \| Achievement of specified clinical and regulatory milestones \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone					$ 57.5
License Agreements \| Archemix \| C5 Licensed Product \| First indication \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone					30.5
License Agreements \| Archemix \| C5 Licensed Product \| Second and third indication \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone					24.5
License Agreements \| Archemix \| C5 Licensed Product \| Sustained delivery applications \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone					2.5
License Agreements \| Archemix \| C5 Licensed Product \| Achievement of specified commercial milestones \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone					$ 22.5
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product
Commitments and contingencies
Amount to be paid on achievement of milestone				$ 23.5
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified commercial sales milestones with respect to a licensed product
Commitments and contingencies
Amount to be paid on achievement of milestone				$ 70.0
Inception 4
Commitments and contingencies
Contingent consideration arrangements, maximum amount		$ 105.0
Contingent consideration arrangements, maximum amount \| shares		7.2
Contingent consideration arrangements, contingently issuable shares as a percentage of shares outstanding		19.90%
Inception 4 \| GA Product
Commitments and contingencies
Clinical and marketing approval milestones		$ 45.0
Inception 4 \| Wet AMD Product
Commitments and contingencies
Clinical and marketing approval milestones		$ 60.0
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Primary Licensed Product \| Specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product
Commitments and contingencies
Payments for license fees			$ 15.7
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Primary Licensed Product \| Specified commercial sales milestones with respect to a licensed product
Commitments and contingencies
Payments for license fees			48.0
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Other Licensed Product \| Specified clinical, marketing approval and reimbursement approval milestones with respect to a licensed product
Commitments and contingencies
Payments for license fees			3.1
Research and development \| BEST1 License Agreement \| University Of Florida Research Foundation (UFRF) And University Of Pennsylvania (Penn) \| Other Licensed Product \| Specified commercial sales milestones with respect to a licensed product
Commitments and contingencies
Payments for license fees			$ 9.6